Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

€50.7 Million in Cash and Cash Equivalents as of March 31, 2017

20170425 PR Q1-2017

Published 25 April 2017
Categorized as 2017, Press release

Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer

20170425 BMS-Clinical Collaboration Release Transgene-FINAL

Published 25 April 2017
Categorized as 2017, Press release, TG4010

SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer

20170424 PR PHOCUS FPI EU – EN

Published 24 April 2017
Categorized as 2017, Pexa-Vec, Press release

Marie Landel and Maya Said Nominated to be Independent Members of Transgene’s Board of Directors

20170419 TG Appointments Board EN

Published 19 April 2017
Categorized as 2017, Press release

Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial

20170412 PR Metro-JX Ph2 EN

Published 12 April 2017
Categorized as 2017, Pexa-Vec, Press release

Transgene Announces Upcoming Investor Meetings and R&D Day

20170410 PR Next investor events

Published 10 April 2017
Categorized as 2017, Press release

Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR Annual Meeting in Washington, DC

20170330-AACR poster EN

Published 30 March 2017
Categorized as 2017, Press release

Major achievements in 2016 validate Transgene’s strategy and provide promising outlook for 2017

20170320 2016 Resultats annuels EN

Published 20 March 2017
Categorized as 2017, Press release

First Patient dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

20170313 FPI Kelly study EN

Published 13 March 2017
Categorized as 2017, Press release, TG4010

Transgene and Léon Bérard Cancer Center Announce Dosing of the First Patient in a Phase 1 Immunotherapy Clinical Trial Evaluating the Intra-Tumoral Co-Administration of Pexa-Vec plus Ipilimumab (Yervoy®) in Solid Cancers

20170213 ISI-JX FPI EN final

Published 13 February 2017
Categorized as 2017, Pexa-Vec, Press release

Posts pagination

Newer posts Page 1 … Page 28 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu